Monte Rosa Therapeutics, Inc. GLUE
9.07 USD -0.09 (-0.98%)
Regular-session close
9.07 0.00 0.00%
After hours · Nov 17, 5:31 PM ET
8.83 Day range 9.28
8.83 52-week range 25.77
- YTD
- -42.16%
- 1 year
- -33.36%
News
seekingalpha.com Monte Rosa: A Risky Contrarian Buy As Market Abandons Bull Thesis Monte Rosa Therapeutics, Inc. remains a risky Buy despite nearly 50% share-price losses since my initial recommendation. MRT-8102's promising biomarker data support further study, although…
seekingalpha.com Monte Rosa Therapeutics: The Market Is Punishing NEK7 For IL-6's Failure Monte Rosa Therapeutics looks mispriced after ZEUS's failure drove a weak read-through to its differently targeted NEK7 degrader, MRT-8102. Gout offers the nearer value inflection: GEMINI-1 initial…
seekingalpha.com Monte Rosa Therapeutics, Inc. (GLUE) Presents at UBS Global Biopharma Conference 2026 Transcript Monte Rosa Therapeutics, Inc. (GLUE) Presents at UBS Global Biopharma Conference 2026 Transcriptbenzinga.com Monte Rosa Therapeutics Presents Preclinical Data Of MRT-8102 At ACR Convergence 2026 Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the presentation of preclinical…
globenewswire.com Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2026 on the Potential of MRT-8102 in Gout NEK7-directed molecular glue degrader inhibited NLRP3 inflammasome activation in human experimental systems and demonstrated anti-inflammatory activity in a rabbit model of gouty arthritis GEMINI-1,…benzinga.com Wells Fargo Maintains Overweight on Monte Rosa Therapeutics, Lowers Price Target to $25 Wells Fargo analyst Derek Archila maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweight and lowers the price target from $27 to $25.
zacks.com Monte Rosa Therapeutics (GLUE) Tops Q3 Earnings and Revenue Estimates Monte Rosa Therapeutics (GLUE) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.1 per share. This compares to a loss of $0.33 per share a year…benzinga.com Monte Rosa Therapeutics Q3 EPS $0.03 Beats $(0.29) Estimate, Sales $54.366M Beat $29.750M Estimate Monte Rosa Therapeutics (NASDAQ:GLUE) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $(0.29) by 110.34 percent. This is a 109.09 percent increase over…
globenewswire.com Monte Rosa Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates Positive GFORCE-1 Phase 1 results showed MRT-8102 reduced key pathogenic drivers of atherosclerotic cardiovascular disease (ASCVD) to levels comparable to healthy volunteers across all three dose…
globenewswire.com Monte Rosa Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today…
zacks.com Wall Street Analysts See a 152.87% Upside in Monte Rosa Therapeutics (GLUE): Can the Stock Really Move This High? The consensus price target hints at a 152.9% upside potential for Monte Rosa Therapeutics (GLUE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in…
globenewswire.com Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today…
zacks.com Monte Rosa Therapeutics (GLUE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release Monte Rosa Therapeutics (GLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.benzinga.com Monte Rosa To Receive $37.5M Milestone Payment From Novartis Following Initiation Of Second Phase 2 Trial Of MRT-6160 In Psoriatic Arthritis Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that its collaborator Novartis has…
benzinga.com Monte Rosa Says Its Collaborator Novartis Initiates Second Phase 2 Clinical Study For VAV1-Directed MGD MRT-6160 In People Living With Active Moderate To Severe Psoriatic Arthritis Phase 2 study to be conducted in participants with active moderate to severe psoriatic arthritisNovartis conducting study under global exclusive development and commercialization license agreement…
globenewswire.com Monte Rosa Therapeutics Announces Milestone Achievement Associated with Second Phase 2 Clinical Study Initiation for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391) Monte Rosa Therapeutics Announces Milestone Achievement Associated with Second Phase 2 Clinical Study Initiation for VAV1-directed Molecular Glue Degrader
defenseworld.net Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stock Has Consensus Target Price of $26.67 According to Analysts Shares of Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE - Get Free Report) have earned an average rating of "Moderate Buy" from the twelve brokerages that are presently covering the stock, Marketbeat…
defenseworld.net ImmunityBio (NASDAQ:IBRX) vs. Monte Rosa Therapeutics (NASDAQ:GLUE) Financial Survey Monte Rosa Therapeutics (NASDAQ: GLUE - Get Free Report) and ImmunityBio (NASDAQ: IBRX - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two…
marketbeat.com Monte Rosa's MRT-8102 Shows Biomarker Gains in GFORCE-1 Study Monte Rosa Therapeutics NASDAQ: GLUE reported results from GFORCE-1, a Phase I study of its NEK7-directed molecular glue degrader MRT-8102 in participants with elevated cardiovascular risk. The…
globenewswire.com Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today…
seekingalpha.com Monte Rosa Therapeutics, Inc. (GLUE) Discusses GFORCE-1 Phase I Results for NEK7 Molecular Glue Degrader MRT-8102 in Cardiovascular Disease Risk Transcript Monte Rosa Therapeutics, Inc. (GLUE) Discusses GFORCE-1 Phase I Results for NEK7 Molecular Glue Degrader MRT-8102 in Cardiovascular Disease Risk Transcript
benzinga.com Monte Rosa Therapeutics Investigational Drug Shows Potential for Cardiovascular Disease Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) reported Phase 1 trial results for its inflammatory disease drug candidate MRT-8102, while outlining plans to advance the treatment into multiple Phase 2…
globenewswire.com Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk In obese subjects at elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1-driven inflammatory diseases,…
globenewswire.com Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk BOSTON, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today…
defenseworld.net Monte Rosa Therapeutics, Inc. $GLUE Shares Newly Acquired by Bank of America Corp DE Bank of America Corp DE purchased a new position in Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) in the undefined quarter, according to the company in its most recent Form 13F filing with the…
